Caroline Seymour

Response predictive subtype–guided treatment identified patient cohorts with breast cancer that were more likely to achieve pCR with Dato-DXd plus durvalumab.

The addition of pembrolizumab to chemotherapy with or without radiation did not improve DFS across the intent-to-treat population of KEYNOTE-B21.

Ramucirumab plus trifluridine/tipiracil failed to improve overall survival vs TAS-102 alone in patients with heavily pretreated metastatic colorectal cancer.

The CheckMate 067 trial of patients with advanced melanoma is the longest follow-up of a checkpoint inhibitor in any tumor type.

AMG 193, an MTA-cooperative PRMT5 inhibitor, demonstrated responses and an acceptable safety profile across patients with MTAP-deleted solid tumors.

Tislelizumab has been approved by the Israeli Ministry of Health for pretreated patients with unresectable or metastatic esophageal squamous cell carcinoma.

The HERTHENA-Lung02 trial met its primary end point of improved PFS with patritumab deruxtecan in pretreated EGFR-mutated non–small cell lung cancer.

The FDA approved adjuvant ribociclib plus a nonsteroidal aromatase inhibitor in patients with HR-positive, HER2-negative early breast cancer.

The Food and Drug Administration approved ribociclib plus an aromatase inhibitor for hormone receptor (HR)–positive, HER2-negative stage II and III early breast cancer that has a high risk of recurrence.

Moshe Ornstein, MD, MA, discusses the implications of updates to NCCN guidelines for the management of non–clear cell and clear cell renal cell carcinoma